Evaluation of full-length, cleaved and nitrosylated serum surfactant Protein D as biomarkers for COPD

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 8, Issue 2, 2011, Pages 79-95

  Duvoix, Annelyse ^a   Miranda, Elena ^b   Perez, Juan ^c   Sorensen, Grith L ^d   Holmskov, Uffe ^d   Trapnell, Bruce C ^e   Madsen, Jens ^f   Clark, Howard W ^f   Edwards, Lisa D ^g   Miller, Bruce E ^g   Tal Singer, Ruth M ^g   Lomas, David A ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF MÁLAGA   (Spain)

^d UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^e CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^f UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^g GLAXOSMITHKLINE   (United States)

Author keywords

Biomarker; COPD; Monoclonal antibodies; Surfactant Protein D

Indexed keywords

MONOCLONAL ANTIBODY; SURFACTANT PROTEIN D;

ADULT; AGED; AIRWAY OBSTRUCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLARA CELL; CONTROLLED STUDY; HOMEOSTASIS; HUMAN; LUNG ALVEOLUS CELL TYPE 2; MAJOR CLINICAL STUDY; MOUSE; NITROSYLATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN CLEAVAGE; PROTEIN SYNTHESIS;

ADULT; AGED; ANIMALS; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; DISEASE PROGRESSION; FORCED EXPIRATORY VOLUME; HUMANS; MICE; MIDDLE AGED; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY SURFACTANT-ASSOCIATED PROTEIN D; STATISTICS, NONPARAMETRIC; VITAL CAPACITY;

EID: 79954457030     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.3109/15412555.2011.558542     Document Type: Article

References (33)

1. Rust K, Grosso L, Zhang V, Chang D, Persson A, Longmore W, Cai GZ, Crouch E. Human surfactant protein D: SP-D contains a C-type lectin carbohydrate recognition domain. Arch Biochem Biophys 1991; 290(1):116-126.
2. Crouch E, Rust K, Marienchek W, Parghi D, Chang D, Persson A. Developmental expression of pulmonary surfactant protein D (SP-D). Am J Respir Cell Mol Biol 1991; 5(1):13-18.
3. Hartshorn K, Chang D, Rust K, White M, Heuser J. Crouch E. Interactions of recombinant human pulmonary surfactant protein Dand SP-Dmultimers with influenza A. AmJ Physiol 1996; 271(5 Pt 1): L753-762.
4. Ferguson JS, Voelker DR, McCormack FX, Schlesinger LS. Surfactant protein D binds toMycobacteriumtuberculosis bacilli and lipoarabinomannan via carbohydrate-lectin interactions resulting in reduced phagocytosis of the bacteria by macrophages. J Immunol 1999; 163(1):312-321. (Pubitemid 29295855)
5. Hartshorn KL, Crouch E, White MR, Colamussi ML, Kakkanatt A, Tauber B, Shepherd V, Sastry KN. Pulmonary surfactant proteins A andDenhance neutrophil uptake of bacteria.AmJ Physiol 1998; 274(6 Pt 1):L958-969.
6. Vandivier RW, Ogden CA, Fadok VA, Hoffmann PR, Brown KK, Botto M, Walport MJ, Fisher JH, Henson PM, Greene KE. Role of surfactant proteins A, D, and C1q in the clearance of apoptotic cells in vivo and in vitro: Calreticulin and CD91 as a common collectin receptor complex. J Immunol 2002; 169(7):3978-3986.
7. Borron PJ, Crouch EC, Lewis JF, Wright JR, Possmayer F, Fraher LJ. Recombinant rat surfactant-associated protein D inhibits human T lymphocyte proliferation and IL-2 production. J Immunol 1998; 161(9):4599-4603. (Pubitemid 28492032)
8. Wu H, Kuzmenko A, Wan S, Schaffer L, Weiss A, Fisher JH, Kim KS,McCormack FX. Surfactant proteins A and D inhibit the growth of Gram-negative bacteria by increasing membrane permeability. J Clin Invest 2003; 111(10):1589-1602. (Pubitemid 38063292)
9. Strong P, Reid KB, Clark H. Intranasal delivery of a truncated recombinant human SP-D is effective at down-regulating allergic hypersensitivity in mice sensitized to allergens of Aspergillus fumigatus. Clin Exp Immunol 2002; 130(1):19-24.
10. Crouch E,Wright JR. Surfactant proteins A and D and pulmonary host defense. Annu Rev Physiol 2001; 63:521-554. (Pubitemid 32304328)
11. Gardai SJ, Xiao YQ, Dickinson M, Nick JA, Voelker DR, Greene KE,Henson PM. By binding SIRPalpha or calreticulin/CD91, lung collectins act as dual function surveillance molecules to suppress or enhance inflammation. Cell 2003; 115(1):13-23. (Pubitemid 37255314)
12. Palaniyar N, Nadesalingam J, Clark H, Shih MJ, Dodds AW, Reid KB. Nucleic acid is a novel ligand for innate, immune pattern recognition collectins surfactant proteins A and D and mannosebinding lectin. J Biol Chem 2004; 279(31):32728-32736. (Pubitemid 39014732)
13. Knudsen L, Ochs M, Mackay R, Townsend P, Deb R, Muhlfeld C, Richter J, Gilbert F, Hawgood S, Reid K, Clark H. Truncated recombinant human SP-D attenuates emphysema and type II cell changes in SP-D deficient mice. Respir Res 2007; 8:70.
14. Leth-Larsen R, Nordenbaek C, Tornoe I, Moeller V, Schlosser A, Koch C, Teisner B, Junker P, Holmskov U. Surfactant protein D (SP-D) serum levels in patients with community-acquired pneumonia small star, filled. Clin Immunol 2003; 108(1):29-37. (Pubitemid 36809213)
15. Miyata M, Sakuma F, Fukaya E, Kobayashi H, Rai T, Saito H, Kasukawa R, Suzuki S. Detection and monitoring of methotrexateassociated lung injury using serum markers KL-6 and SP-D in rheumatoid arthritis. Intern Med 2002; 41(6):467-473. (Pubitemid 34727578)
16. Umetani K, Abe M, Kawabata K, Iida T, Kohno I, Sawanobori T, Kugiyama K. SP-D as a marker of amiodarone-induced pulmonary toxicity. Intern Med 2002; 41(9):709-712.
17. OhnishiH, YokoyamaA, Kondo K,Hamada H,AbeM,Nishimura K, Hiwada K, Kohno N. Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. Am J Respir Crit Care Med 2002; 165(3):378-381. (Pubitemid 34118512)
18. Krane M, Griese M. Surfactant protein D in serumfrompatients with allergic bronchopulmonary aspergillosis. Eur Respir J 2003; 22(4):592-595. (Pubitemid 37258535)
19. Sims MW, Tal-Singer RM, Kierstein S, Musani AI, Beers MF, Panettieri RA, Haczku A. Chronic obstructive pulmonary disease and inhaled steroids alter surfactant protein D (SP-D) levels: a cross-sectional study. Respir Res 2008; 9:13.
20. Lomas DA, Silverman EK, Edwards LD, Locantore NW, Miller BE, Horstman DH, Tal-Singer R. Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD. Eur Respir J 2009; 34(1):95-102.
21. Sin DD, Man SF, Marciniuk DD, Ford G, FitzGerald M, Wong E, York E, Mainra RR, Ramesh W, Melenka LS, Wilde E, Cowie RL, Williams D, Gan WQ, Rousseau R. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177(11):1207-1214. (Pubitemid 351860929)
22. Cooley J, McDonald B, Accurso FJ, Crouch EC, Remold-O'Donnell E. Patterns of neutrophil serine protease-dependent cleavage of surfactant protein D in inflammatory lung disease. J Leukoc Biol 2008; 83(4):946-955. (Pubitemid 351959875)
23. Duvoix A, Mackay RM, Henderson N, McGreal E, Postle A, Reid K, Clark H. Physiological concentration of calcium inhibits elastase-induced cleavage of a functional recombinant fragment of surfactant protein D. Immunobiology 2011; Epub ahead of print. doi: 10.1164/reem.201008-12200C.
24. Tecle T,White MR, Sorensen G, Gantz D, Kacak N, Holmskov U, Smith K, Crouch EC,Hartshorn KL. Critical role for cross-linking of trimeric lectin domains of surfactant protein D in antiviral activity against influenza A virus. Biochem J 2008; 412(2):323-329. (Pubitemid 351758238)
25. Perez J, Garrido O, Cifuentes M, Alonso FJ, Estivill-Torrus G, Eller G, Nualart F, Lopez-Avalos MD, Fernandez-Llebrez P, Rodriguez EM. Bovine Reissner's fiber (RF) and the central canal of the spinal cord: An immunocytochemical study using a set of monoclonal antibodies against the RF-glycoproteins. Cell Tissue Res 1996; 286(1):33-42. (Pubitemid 26345200)
26. Vestbo J, Anderson W, Coxson HO, Crim C, Dawber F, Edwards L, Hagan G, Knobil K, Lomas DA,MacNeeW, Silverman EK, Tal-Singer R. Evaluation of COPD longitudinally to identify predictive surrogate end-points (ECLIPSE). Eur Respir J 2008; 31(4):869-873.
27. American Thoracic Society. Standardization of spirometry. Am J Respir Crit Care Med 1994; 152:1107-1136.
28. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, Zielinski J. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176(6):532-555. (Pubitemid 47403272)
29. Atochina-Vasserman EN, Gow AJ, Abramova H, Guo CJ, Tomer Y, Preston AM, Beck JM, Beers MF. Immune reconstitution during Pneumocystis lung infection: disruption of surfactant component expression and function by S-nitrosylation. J Immunol 2009; 182(4):2277-2287.
30. Keen C, Gustafsson P, Lindblad A, Wennergren G, Olin AC. Low levels of exhaled nitric oxide are associated with impaired lung function in cystic fibrosis. Pediatr Pulmonol 45(3):241-248.
31. Smith AD, Cowan JO, Brassett KP, Herbison GP, Taylor DR. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med 2005; 352(21):2163-2173.
32. Syk J, Unden AL, Alving K. Relationship between exhaled nitric oxide and IgE sensitisation in patients with asthma: influence of steroid treatment. Clin Respir J 2009; 3(3):143-151.
33. Guo CJ, Atochina-Vasserman EN, Abramova E, Foley JP, Zaman A, Crouch E, Beers MF, Savani RC, Gow AJ. S-nitrosylation of surfactant protein-D controls inflammatory function. PLoS Biol 2008; 6(11):e266.